Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India. (PubMed, Indian J Cancer) - Oct 1, 2026 - "In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 - EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies."
Clinical • Clinical data • Journal • Observational data • Real-world evidence • Retrospective data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia
|
|
Anbarasan Sekar; Anuradha Mehta; Ayushi Sahay; Debdeep Samaddar; George John; Palak Popat; Prabhat Bhargava; Purvi Haria; Rajiv Sarin; Revathy Krishnamurthy; Rima Pathak; Shalaka Joshi; Sudeep Gupta; Sushmita Rath; Tabassum Wadasadawala
|